Alzheimer's Therapeutics Market Size Expected to Surpass USD 8.18 Bn by 2032 [Yahoo! Finance]
Biogen Inc. (BIIB)
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
biogen.com/en_us/investors.html
Company Research
Source: Yahoo! Finance
Ottawa, April 18, 2024 (GLOBE NEWSWIRE) -- The global alzheimer's therapeutics market size was valued at USD 4.82 billion in 2023 and is predicted to hit around USD 7.52 billion by 2031, a study published by Towards Healthcare a sister firm of Precedence Research. Report Highlights Cholinesterase inhibitors lead the market with a commanding 50% market share in 2023. Combination drugs are projected to register the fastest growth with 6.2% CAGR over the forecast period. Hospital pharmacies were the largest contributors to the market in 2023. The National Center for Biotechnology Information reported that in 2021, around 6.2 million Americans aged 65 and older had Alzheimer's disease. By 2060, this number is expected to double to about 13.8 million nearly. Women are more likely to get Alzheimer's because they tend to live longer. Alzheimer's is becoming the top cause of death among neurodegenerative diseases and can lead to physical disability, needing prompt treatment. Alzh
Show less
Read more
Impact Snapshot
Event Time:
BIIB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIIB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
News
- Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]Yahoo! Finance
- Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings [Seeking Alpha]Seeking Alpha
- Biogen: Don't Overthink This One [Seeking Alpha]Seeking Alpha
- Biogen Inc. (NASDAQ: BIIB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $270.00 price target on the stock.MarketBeat
- Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade) [Seeking Alpha]Seeking Alpha
BIIB
Earnings
- 4/25/24 - Beat
BIIB
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- BIIB's page on the SEC website